The Brokerages Set Celldex Therapeutics Inc. (NASDAQ:CLDX) PT at $9.75

The Brokerages Set Celldex Therapeutics Inc. (NASDAQ:CLDX) PT at $9.75

Celldex Therapeutics Inc. (NASDAQ:CLDX) has earned a consensus recommendation of “Hold” from the eleven brokerages that are covering the firm. Six investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $9.75.

Several research analysts have recently issued reports on the company. Jefferies Group reaffirmed a “hold” rating and issued a $5.00 price objective (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Wedbush reaffirmed a “neutral” rating and issued a $3.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Finally, Brean Capital assumed coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They issued a “buy” rating and a $16.00 price objective for the company.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.14 on Thursday. Celldex Therapeutics has a 12-month low of $2.96 and a 12-month high of $18.62. The firm’s market capitalization is $416.26 million. The stock has a 50 day moving average of $3.75 and a 200-day moving average of $4.17.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The company earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. The firm’s revenue was down 36.4% compared to the same quarter last year. On average, equities research analysts predict that Celldex Therapeutics will post ($1.34) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY boosted its position in Celldex Therapeutics by 2.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,903 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 1,412 shares during the last quarter. Zacks Investment Management boosted its position in Celldex Therapeutics by 2.3% in the second quarter. Zacks Investment Management now owns 68,681 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,517 shares during the last quarter. National Planning Corp boosted its position in Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,650 shares during the last quarter. Teachers Advisors Inc. boosted its position in Celldex Therapeutics by 3.9% in the second quarter. Teachers Advisors Inc. now owns 164,942 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 6,148 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Celldex Therapeutics by 1.7% in the first quarter. Geode Capital Management LLC now owns 669,587 shares of the biopharmaceutical company’s stock worth $2,531,000 after buying an additional 10,982 shares during the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.

Related posts

Leave a Comment